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The tools of molecular biology have proven readily
adaptable for use in the clinical diagnostic laboratory and
promise to be extremely useful in diagnosis, therapy, and
epidemiologic investigations and infection control (1,2).
Although technical issues such as ease of performance,
reproducibility, sensitivity, and specificity of molecular tests
are important, cost and potential contribution to patient care
are also of concern (3). Molecular methods may be an
improvement over conventional microbiologic testing in many
ways. Currently, their most practical and useful application
is in detecting and identifying infectious agents for which
routine growth-based culture and microscopy methods may
not be adequate (4-7).
Nucleic acid-based tests used in diagnosing infectious
diseases use standard methods for isolating nucleic acids
from organisms and clinical material and restriction
endonuclease enzymes, gel electrophoresis, and nucleic acid
hybridization techniques to analyze DNA or RNA (6). Because
the target DNA or RNA may be present in very small amounts
in clinical specimens,  various signal amplification and target
amplification techniques have been used to detect infectious
agents in clinical diagnostic laboratories (5,6). Although
mainly a research tool, nucleic acid sequence analysis coupled
with target amplification is clinically useful and helps detect
and identify previously uncultivatable organisms and
characterize antimicrobial resistance gene mutations, thus
aiding both diagnosis and treatment of infectious diseases
(5,8,9). Automation and high-density oligonucleotide probe
arrays (DNA chips) also hold great promise for characterizing
microbial pathogens (6).
Although most clinicians and microbiologists enthusias-
tically welcome the new molecular tests for diagnosing
infectious disease, the high cost of these tests is of concern (3).
Despite the probability that improved patient outcome and
reduced cost of antimicrobial agents and length of hospital
stay will outweigh the increased laboratory costs incurred
through the use of molecular testing, such savings are
difficult to document (3,10,11). Much of the justification for
expenditures on molecular testing is speculative (11);
however, the cost of equipment, reagents, and trained
personnel is real and substantial, and reimbursement issues
are problematic (3,11).  Given these concerns, a facility’s need
for molecular diagnostic testing for infectious diseases should
be examined critically by the affected clinical and laboratory
services. In many instances, careful overseeing of test
ordering and prudent use of a reference laboratory may be the
most viable options.
Practical Applications of Molecular Methods
in the Clinical Microbiology Laboratory
Commercial kits for the molecular detection and
identification of infectious pathogens have provided a degree
of standardization and ease of use that has facilitated the
introduction of molecular diagnostics into the clinical
microbiology laboratory (Table 1). The use of nucleic acid
probes for identifying cultured organisms and for direct
detection of organisms in clinical material was the first
exposure that most laboratories had to commercially
available molecular tests.  Although these probe tests are still
widely used, amplification-based methods are increasingly
employed for diagnosis, identification and quantitation of
pathogens, and characterization of antimicrobial-drug
resistance genes.  Commercial amplification kits are
available for some pathogens (Table 1), but some clinically
important pathogens require investigator-designed or “home-
brew” methods (Table 2). In addition, molecular strain typing,
or genotyping, has proven useful in guiding therapeutic
decisions for certain viral pathogens and for epidemiologic
investigation and infection control (2,12).
Detection and Identification of Pathogens Without Target
Amplification
Commercial kits containing non-isotopically labeled
nucleic acid probes are available for direct detection of
pathogens in clinical material and identification of organisms
after isolation in culture (Table 1). Use of solution-phase
hybridization has allowed tests to be performed singly or in
batches in a familiar microwell format.
Although direct detection of organisms in clinical
specimens by nucleic acid probes is rapid and simple, it
suffers from lack of sensitivity. Most direct probe detection
assays require at least 104 copies of nucleic acid per microliter
for reliable detection, a requirement rarely met in clinical
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presented in an enzyme immunoassay-like format and
include branched chain DNA probes (Chiron) and QB
replicase (Gene-Trak) methods (Table 1). These methods are
not as sensitive as target amplification-based methods for
detection of viruses; however, the quantitative results have
proven useful for determining viral load and prognosis and for
monitoring response to therapy (13).
Probe hybridization is useful for identifying slow-
growing organisms after isolation in culture using either
liquid or solid media. Identification of mycobacteria and other
slow-growing organisms such as the dimorphic fungi
(Histoplasma capsulatum, Coccidioides immitis, and Blasto-
myces dermatitidis) has certainly been facilitated by
commercially available probes. All commercial probes for
identifying organisms are produced by Gen-Probe and use
acridinium ester-labeled probes directed at species-specific
rRNA sequences (Table 1). Gen-Probe products are available
for the culture identification of Mycobacterium tuberculosis,
M. avium-intracellulare complex, M. gordonae, M. kansasii,
Cryptococcus neoformans, the dimorphic fungi (listed above),
N. gonorrhoeae, Staphylococcus aureus, Streptococcus
pneumoniae, Escherichia coli, Haemophilus influenzae,
Enterococcus spp., S. agalactiae, and Listeria monocytogenes.
The sensitivity and specificity of these probes are excellent,
and they provide species identification within one working
day. Because most of the bacteria listed, plus C. neoformans,
can be easily and efficiently identified by conventional
methods within 1 to 2 days, many of these probes have not
been widely used. The mycobacterial probes, on the other
hand, are accepted as mainstays for the identification of
M. tuberculosis and related species (7).
Table 1. FDA-approved molecular diagnostic tests for infectious diseasea
Test Method Companyb
Chlamydia trachomatis PCRc Roche
  detection LCR Abbott
TMA Gen-Probe
Hybrid capture Digene
Neisseria gonorrhoeae LCR Abbott
  detection Hybrid capture Digene
C. trachomatis/ Hybridization Gen-Probe
  N. gonorrhoeae SDR Becton-Dickinson
  screening/detection
Mycobacterium PCR Roche
  tuberculosis detection TMA Gen-Probe
HPV screening Hybrid capture Digene
CMV Hybrid capture Digene
NASBA Organon Teknika
Group A strep detection Hybridization Gen-Probe
HIV quantitation PCR Roche
Gardnerella, Trichomonas Hybridization Becton-Dickinson
  vaginalis, and
  Candida
Culture confirmation Hybridization Gen-Probe
  for bacteria and
  fungi
LCR = ligase chain reaction; TMA = transcription-mediated
amplification; SDR = strand displacement reaction; NASBA = nucleic
acid strand-based amplification.
aThe table contains examples of commercially available methods and is
not intended to be all-inclusive. Websites of the principle manufacturers
are a useful source of the most up-to-date information.
bCompanies: Digene, Silver Spring, MD; Chiron, Emeryville, CA;
Roche, Branchburg, NJ; Organon Teknika, Durham, NC; Murex/
Abbott, Abbott Park, IL; Gen-Probe, San Diego, CA; Abbott, Abbott
Park, IL; Becton-Dickinson, Cockeysville, MD.
cPCR = polymerase chain reaction.
Table 2. Noncommercial nucleic acid-based tests for clinically important
viral and bacterial pathogensa
Organism Specimen type Clinical indication
Epstein-Barr virus Cerebrospinal EBV lymphoproli-
  (EBV)   fluid (CSF)   ferative disorder
Herpes simplex virus CSF Encephalitis
  (HSV) types 1 and 2 Vitreous humor
Varicella-zoster virus Various tissues VZV reactivation
  virus (VZV)
JCV CSF Progressive multi-
  focal leuko-
  encephalopathy
Enterovirus CSF Aseptic meningitis
Parvovirus B19 Amniotic fluid Hydrops fetalis
Serum Anemia
Adenovirus Urine Immunocompro-
Tissues   mised patients,
Blood   transplant
  recipients
Ehrlichia Blood Human granulocytic
  and monocytic
  ehrlichiosis
Bordetella pertussis Nasopharyngeal Whooping cough
  aspirate
Legionella pneumophila Respiratory Atypical pneumonia
Chlamydia pneumoniae Respiratory Atypical pneumonia
Mycoplasma pneumoniae Respiratory Atypical pneumonia
Helicobacter pylori Gastric fluid Peptic ulcer disease
Stool
aAll tests use polymerase chain reaction. The list is not all-inclusive.
samples without some form of amplification. Amplification of
the detection signal after probe hybridization improves
sensitivity to as low as 500 gene copies per microliter and
provides quantitative capabilities. This approach has been
used extensively for quantitative assays of viral load (HIV,
hepatitis B virus [HBV] and hepatitis C virus [HCV]) (Table
1) but does not match the analytical sensitivity of target
amplification-based methods, such as polymerase chain
reaction (PCR), for detecting organisms.
The commercial probe systems that use solution-phase
hybridization and chemiluminescence for direct detection of
infectious agents in clinical material include the PACE2
products of Gen-Probe and the hybrid capture assay systems
of Digene and Murex (Table 1). These systems are user
friendly, have a long shelf life, and are adaptable to small or
large numbers of specimens. The PACE2 products are
designed for direct detection of both Neisseria gonorrhoeae
and  Chlamydia trachomatis in a single specimen (one
specimen, two separate probes). The hybrid capture systems
detect human papillomavirus (HPV) in cervical scrapings,
herpes simplex virus (HSV) in vesicle material, and
cytomegalovirus (CMV) in blood and other fluids. All these
tests have demonstrated sensitivity exceeding that of culture
or immunologic methods for detecting the respective
pathogens but are less sensitive than PCR or other target
amplification-based methods.
The signal amplification-based probe methods for
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Nucleic Acid Amplification
Nucleic acid amplification provides the ability to
selectively amplify specific targets present in low concentra-
tions to detectable levels; thus, amplification-based methods
offer superior performance, in terms of sensitivity, over the
direct (non-amplified) probe-based tests. PCR (Roche
Molecular Systems, Branchburg, NJ) was the first such
technique to be developed and because of its flexibility and
ease of performance remains the most widely used molecular
diagnostic technique in both research and clinical laborato-
ries. Several different amplification-based strategies have
been developed and are available commercially (Table 1).
Commercial amplification-based molecular diagnostic sys-
tems for infectious diseases have focused largely on systems
for detecting N. gonorrhoeae, C. trachomatis, M. tuberculosis,
and specific viral infections (HBV, HCV, HIV, CMV, and
enterovirus) (Table 1). Given the adaptability of PCR,
numerous additional infectious pathogens have been detected
by investigator-developed or home-brew PCR assays (5)
(Table 2). In many instances, such tests provide important
and clinically relevant information that would otherwise be
unavailable since commercial interests have been slow to
expand the line of products available to clinical laboratories.
In addition to qualitative detection of viruses, quantitation of
viral load in clinical specimens is now recognized to be of great
importance for the diagnosis, prognosis, and therapeutic
monitoring for HCV, HIV, HBV, and CMV (13). Both PCR and
nucleic acid strand-based amplification systems are available
for quantitation of one or more viruses (Table 1).
The adaptation of amplification-based test methods to
commercially available kits has served to optimize user
acceptability, prevent contamination, standardize reagents
and testing conditions, and make automation a possibility. It
is not clear to what extent the levels of detection achievable by
the different amplification strategies differ. None of the
newer methods provides a level of sensitivity greater than
that of PCR. In choosing a molecular diagnostic system, one
should consider the range of tests available, suitability of the
method to workflow, and cost (6). Choosing one amplification-
based method that provides testing capabilities for several
pathogens is certainly practical.
Amplification-based methods are also valuable for
identifying cultured and uncultivatable organisms (5).
Amplification reactions may be designed to rapidly identify
an acid-fast organism as M. tuberculosis or may amplify a
genus-specific or “universal” target, which then is character-
ized by using restriction endonuclease digestion, hybridiza-
tion with multiple probes, or sequence determination to
provide species or even subspecies delineation (4,5,14).
Although identification was initially applied to slow-growing
mycobacteria, it has applications for other pathogens that are
difficult or impossible to identify with conventional methods.
Detecting Antimicrobial-Drug Resistance
Molecular methods can rapidly detect antimicrobial-drug
resistance in clinical settings and have substantially
contributed to our understanding of the spread and genetics of
resistance (9). Conventional broth- and agar-based antimicro-
bial susceptibility testing methods provide a phenotypic
profile of the response of a given microbe to an array of agents.
Although useful for selecting potentially useful therapeutic
agents, conventional methods are slow and fraught with
problems. The most common failing is in the detection of
methicillin resistance in staphylococci, which may be
expressed in a very heterogeneous fashion, making
phenotypic characterization of resistance difficult (9,15).
Currently, molecular detection of the resistance gene, mec A,
is the standard against which phenotypic methods for
detection of methicillin resistance are judged (9,15,16).
Molecular methods may be used to detect specific
antimicrobial-drug resistance genes (resistance genotyping)
in  many organisms (Table 3) (8,9). Detection of specific point
mutations associated with resistance to antiviral agents is
also increasingly important (17,18). Screening for mutations
in an amplified product may be facilitated by the use of high-
density probe arrays (Gene chips) (6).
Despite its many potential advantages, genotyping will
not likely replace phenotypic methods for detecting
antimicrobial-drug resistance in the clinical laboratory in the
near future.  Molecular methods for resistance detection may
be applied directly to the clinical specimen, providing
simultaneous detection and identification of the pathogen
plus resistance characterization (9). Likewise, they are useful
in detecting resistance in viruses, slow-growing or nonviable
organisms, or organisms with resistance mechanisms that
are not reliably detected by phenotypic methods (9,19).
However, because of their high specificity, molecular methods
will not detect newly emerging resistance mechanisms and
are unlikely to be useful in detecting resistance genes in
species where the gene has not been observed previously (19).
Furthermore, the presence of a resistance gene does not mean
that the gene will be expressed, and the absence of a known
resistance gene does not exclude the possibility of resistance
from another mechanism. Phenotypic antimicrobial suscepti-
bility testing methods allow laboratories to test many
organisms and detect newly emerging as well as established
resistance patterns.
Molecular Epidemiology
Laboratory characterization of microbial pathogens as
biologically or genetically related is frequently useful in
investigations (12,20,21). Several different epidemiologic
typing methods have been applied in studies of microbial
pathogens (Table 4). The phenotypic methods have
occasionally been useful in describing the epidemiology of
infectious diseases; however, they are too variable, slow, and
labor-intensive to be of much use in most epidemiologic
investigations. Newer DNA-based typing methods have
eliminated most of these limitations and are now the
preferred techniques for epidemiologic typing. The most
widely used molecular typing methods include plasmid
profiling, restriction endonuclease analysis of plasmid and
genomic DNA, Southern hybridization analysis using specific
DNA probes, and chromosomal DNA profiling using either
pulsed-field gel electrophoresis (PFGE) or PCR-based
methods (12,20). All these methods use electric fields to
separate DNA fragments, whole chromosomes, or plasmids
into unique patterns or fingerprints that are visualized by
staining with ethidium bromide or by nucleic acid probe
hybridization (Figure 1). Molecular typing is performed to
determine whether different isolates give the same or
different results for one or more tests. Epidemiologically
related isolates share the same DNA profile or fingerprint,
whereas sporadic or epidemiologically unrelated isolates
have distinctly different patterns (Figure). If isolates from
different patients share the same fingerprint, they probably315 Vol. 7, No. 2, March–April 2001 Emerging Infectious Diseases
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Table 3. Molecular methods for detecting antimicrobial resistancea
Organism(s)     Antimicrobial agent(s) Gene Detection method
Staphylococci Methicillin mec Ab Standard DNA probe
Oxacillin Branched chain DNA probe
PCR
Enterococci Vancomycin van A, B, C, Dc Standard DNA probe
PCR
Enterobacteriaceae Beta-lactams blaTEM and blaSHV
d Standard probe
Haemophilus influenzae PCR and RFLP
Neisseria gonorrhoeae PCR and sequencing
Enterobacteriaceae and Quinolones Point mutations in gyr A, gyr B, PCR and sequencing
  gram-positive cocci   par C and par E
Mycobacterium tuberculosise Rifampin Point mutations in rpo B PCR and SSCP
PCR and sequencing
Isoniazid Point mutations in kat G, inh A, and ahp C PCR and SSCP
Ethambutol Point mutations in emb B PCR and sequencing
Streptomycin Point mutations in rps L and rrs PCR and RFLP
Herpes virusesf Acyclovir and related drugs Mutations or deletions in the TK gene PCR and sequencing
Foscarnet Point mutations in DNA polymerase gene PCR and sequencing
HIVg Nucleoside reverse Point mutations in RT gene PCR and sequencing
  transcriptase inhibitors PCR and LIPA
Protease inhibitors Point mutations in PROT gene PCR and sequencing
aAdapted from Pfaller (2).
bmecA encodes for the altered penicillin binding protein PBP2a'; phenotypic methods may require 48 hours incubation or more to detect
resistance and are less than 100% sensitive. Detection of mecA has potential for clinical application in specific circumstances.
cVancomycin resistance in enterococci may be related to one of four distinct resistance genotypes of which vanA and vanB are most important.
Genotypic detection of resistance is useful in validation of phenotypic methods.
dThe genetic basis of resistance to beta-lactam antibiotics is extremely complex. The blaTEM and blaSHV genes are the two most common sets of
plasmid encoded beta-lactamases.  The presence of either a blaTEM or blaSHV gene implies ampicillin resistance. Variants of the blaTEM and
blaSHV genes (extended spectrum beta-lactamases) may also encode for resistance to a range of third-generation cephalosporins and to
monobactams.
eM. tuberculosis is very slow growing. Four weeks or more may be required to obtain phenotypic susceptibility test results. Detection of
resistance genes in M. tuberculosis has potential for clinical application in the short term.
fThere are no phenotypic methods sufficiently practical for routine clinical detection of resistance to antiviral agents. Genotypic methods
represent a practical method for routine detection of antiviral resistance.
gAbbreviations not defined in text: RFLP, restriction fragment length polymorphism; SSCP, single-stranded conformational polymorphism;
LIPA, line probe assay; TK, thymidine kinase; RT, reverse transcriptase; PROT, protease.
Table 4. Genotypic methods for epidemiologic typing of microorganismsa,b
Method Examples Comments
Plasmid analysis Staphylococci Plasmids may be digested with restriction endonucleases
Enterobacteriaceae Only useful when organisms carry plasmids
Restriction endonuclease analysis of chromosomal Enterococci Large number of bands
  DNA with conventional electrophoresis Staphylococcus aureus Difficult to interpret
Clostridium difficile Not amenable to computer analysis
Candida spp.
PFGE Enterobacteriaceae Fewer bands
Staphylococci Amenable to computer analysis
Enterococci Very broad application
Candida spp.
Genome restriction fragment length polymorphism Enterobacteriaceae Fewer bands
  analysis: ribotyping, insertion sequence probe Staphylococci Computer analysis
  fingerprinting Pseudomonas aeruginosa Sequence-based profiles
Mycobacterium tuberculosis Automated
Candida spp.
PCR-based methods: repetitive elements PCR Enterobacteriaceae Crude extracts and small amounts of DNA may suffice
  spacer typing, selective amplification of genome Acinetobacter spp.
  restriction fragments, multilocus allelic Staphylococci
  sequence-based typing M. tuberculosis
HCV
Library probe genotypic hybridization schemes: Burkholderia cepacia Unambiguous yes-no result
  multilocus probe dot-blot patterns, high-density S. aureus Less discrimination than other methods
  oligonucleotide patterns M. tuberculosis Couple with DNA chip technology
aThe table contains examples of available methods and applications and is not intended to be all-inclusive.
bAdapted from Pfaller (2).316 Emerging Infectious Diseases Vol. 7, No. 2, March–April 2001
Special Issue
originated from the same clone and were transmitted from
patient to patient by a common source or mechanism.
Molecular typing methods have allowed investigators to
study the relationship between colonizing and infecting
isolates in individual patients, distinguish contaminating
from infecting strains, document nosocomial transmission in
hospitalized patients, evaluate reinfection versus relapse in
patients being treated for an infection, and follow the spread
of antimicrobial-drug resistant strains within and between
hospitals over time (12). Most available DNA-based typing
methods may be used in studying nosocomial infections when
applied in the context of a careful epidemiologic investigation
(12,21). In contrast, even the most powerful and sophisticated
typing method, if used indiscriminately in the absence of
sound epidemiologic data, may provide conflicting and
confusing information.
Financial Considerations
Molecular testing for infectious diseases includes testing
for the host’s predisposition to disease, screening for infected
or colonized persons, diagnosis of clinically important
infections, and monitoring the course of infection or the
spread of a specific pathogen in a given population. It is often
assumed that in addition to improved patient care, major
financial benefits may accrue from molecular testing because
the tests reduce the use of less sensitive and specific tests,
unnecessary diagnostic procedures and therapies, and
nosocomial infections (11). However, the inherent costs of
molecular testing methods, coupled with variable and
inadequate reimbursement by third-party payers and
managed-care organizations, have limited the introduction of
these tests into the clinical diagnostic laboratory.
Not all molecular diagnostic tests are extremely
expensive. Direct costs vary widely, depending on the test’s
complexity and sophistication. Inexpensive molecular tests
are generally kit based and use methods that require little
instrumentation or technologist experience. DNA probe
methods that detect C. trachomatis or N. gonorrhoeae are
examples of low-cost molecular tests. The more complex
molecular tests, such as resistance genotyping, often have
high labor costs because they require experienced, well-
trained technologists. Although the more sophisticated tests
may require expensive equipment (e.g., DNA sequencer) and
reagents, advances in automation and the production of less-
expensive reagents promise to decrease these costs as well as
technician time. Major obstacles to establishing a molecular
diagnostics laboratory that are often not considered until late
in the process are required licenses, existing and pending
patents, test selection, and billing and reimbursement (22).
Reimbursement issues are a major source of confusion,
frustration, and inconsistency. Reimbursement by third-
party payers is confounded by lack of Food and Drug
Administration (FDA) approval and Current Procedural
Terminology (CPT) codes for many molecular tests. In
general, molecular tests for infectious diseases have been
more readily accepted for reimbursement; however, reim-
bursement is often on a case-by-case basis and may be slow
and cumbersome. FDA approval of a test improves the likelihood
that it will be reimbursed but does not ensure that the amount
reimbursed will equal the cost of performing the test.
Perhaps more than other laboratory tests, molecular
tests may be negatively affected by fee-for-service managed-
care contracts and across-the-board discounting of laboratory
test fees. Such measures often result in reimbursement that
is lower than the cost of providing the test. Although
molecular tests may be considered a means of promoting
patient wellness, the financial benefits of patient wellness are
not easily realized in the short term (11). Health maintenance
organizations (HMOs) and managed-care organizations often
appear to be operating on shorter time frames, and their
administrators may not be interested in the long-term impact
of diagnostic testing strategies.
Molecular screening programs for infectious diseases are
developed to detect symptomatic and asymptomatic disease
in individuals and groups. Persons at high risk, such as
immunocompromised patients or those attending family
planning or obstetrical clinics, are screened for CMV and
Chlamydia, respectively. Likewise, all blood donors are
screened for bloodborne pathogens. The financial outcome of
such testing is unknown. The cost must be balanced against
the benefits of earlier diagnosis and treatment and societal
issues such as disease epidemiology and population
management.
One of the most highly touted benefits of molecular
testing for infectious diseases is the promise of earlier
detection of certain pathogens. The rapid detection of
M. tuberculosis directly in clinical specimens by PCR or other
amplification-based methods is quite likely to be cost-
effective in the management of tuberculosis (7). Other
examples of infectious disease that are amenable to molecular
diagnosis and for which management can be improved by this
technology include HSV encephalitis, Helicobacter pylori
infection, and neuroborreliosis caused by Borrelia burgdorferi.
For HSV encephalitis, detection of HSV in cerebrospinal fluid
(CSF) can direct specific therapy and eliminate other tests
including brain biopsy. Likewise, detection of H. pylori in
gastric fluid can direct therapy and obviate the need for
endoscopy and biopsy. PCR detection of B. burgdorferi in CSF
is helpful in differentiating neuroborreliosis from other
chronic neurologic conditions and chronic fatigue syndrome.
As discussed earlier, molecular tests may be used to
predict disease response to specific antimicrobial therapy.
Detection of specific resistance genes (mec A, van A) or point
mutations resulting in resistance has proven efficacious in
managing disease. Molecular-based viral load testing has
Figure. Pulsed-field gel electrophoresis (PFGE) profiles of
Staphylococcus aureus isolates digested with Sma 1. A variety of
PFGE profiles are demonstrated in these 23 isolates.317 Vol. 7, No. 2, March–April 2001 Emerging Infectious Diseases
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become standard practice for patients with chronic hepatitis
and AIDS. Viral load testing and genotyping of HCV are
useful in determining the use of expensive therapy such as
interferon and can be used to justify decisions on extent and
duration of therapy. With AIDS, viral load determinations
plus resistance genotyping have been used to select among the
various protease inhibitor drugs available for treatment,
improving patient response and decreasing incidence of
opportunistic infections.
Pharmacogenomics is the use of molecular-based tests to
predict the response to specific therapies and to monitor the
response of the disease to the agents administered. The best
examples of pharmacogenomics in infectious diseases are the
use of viral load and resistance genotyping to select and
monitor antiviral therapy of AIDS and chronic hepatitis
(17,18). This application improves disease outcome; shortens
length of hospital stay; reduces adverse events and toxicity;
and facilitates cost-effective therapy by avoiding unnecessary
expensive drugs, optimizing doses and timing, and
eliminating ineffective drugs.
Molecular strain typing of microorganisms is now well
recognized as an essential component of a comprehensive
infection control program that also involves the infection
control department, the infectious disease division, and
pharmacy (10, 21). Molecular techniques for establishing
presence or absence of clonality are effective in tracking the
spread of nosocomial infections and streamlining the
activities of the infection control program (21,23). A
comprehensive infection control program uses active
surveillance by both infection control practitioners and the
clinical microbiology laboratory to identify clusters of
infections with a common microbial phenotype (same species
and antimicrobial susceptibility profile). The isolates are
then characterized in the laboratory by using one of a number
of molecular typing methods (Table 4) to confirm or refute
clonality. Based on available epidemiologic and molecular
data, the hospital epidemiologist then develops an
intervention strategy. Molecular typing can shorten or
prevent an epidemic (23) and reduce the number and cost of
nosocomial infections (Table 5) (10). Hacek et al. (10)
analyzed the medical and economic benefits of an infection
control program that included routine determination of
microbial clonality and found that nosocomial infections were
significantly decreased and more than $4 million was saved
over a 2-year period (Table 5).
The true financial impact of molecular testing will only be
realized when testing procedures are integrated into total
disease assessment. More expensive testing procedures may
be justified if they reduce the use of less sensitive and less
specific tests and eliminate unnecessary diagnostic proce-
dures and ineffective therapies.
Dr. Pfaller is professor and director of the Molecular Epidemiology
and Fungus Testing Laboratory at the University of Iowa College of
Medicine and College of Public Health. His research focuses on the epi-
demiology of nosocomial infections and antimicrobial-drug resistance.
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